期刊文献+

粪便MMP-9对溃疡性结肠炎诊断价值的分析 被引量:3

Diagnostic value of fecal MMP-9 in ulcerative colitis
原文传递
导出
摘要 目的比较溃疡性结肠炎患者、功能性胃肠功能紊乱患者和正常对照组的粪便中基质金属蛋白酶-9(MMP-9)水平,研究其与疾病活动性、钙卫蛋白的相关性。方法选取衢州市人民医院2012年-2013年UC患者48例,IBS-D患者25例,正常健康人25例进行研究,并用Mayo得分评价UC严重性,检测粪便MMP-9和钙卫蛋白,然后进行统计学分析。结果正常对照组和IBS-D患者粪便MMP-9低于检测限或低于0.22 ng/ml,UC患者粪便MMP-9与Mayo(P<0.001)、内镜检查(P<0.001)和CRP(P=0.002)得分明显相关。此外,UC患者MMP-9与粪便钙卫蛋白亦有一定的相关性(r=0.492,P=0.013)。结论粪便MMP-9可成为区别UC、IBS-D患者和正常对照组的一个非侵入的有用指标,并可用来判断疾病活动性。 Objective To compare the fecal MMP-9 levels in ulcerative colitis( UC) patients,patients with functional gastrointestinal disorder( IBS-D patients as example) and healthy controls,so as to study the correlation between fecal MMP-9 level and disease activity,calprotectin. Methods From 2012 to 2013,48 UC patients,25 patients with diarrhea-predominant irritable bowel syndrome( IBS-D) and 25 healthy controls were selected to detect the levels of fecal MMP-9 and calprotectin, then the results were analyzed by statistics. Mayo score was used to evaluate the disease severity of UC patients. Results Fecal MMP-9 was undetectable or less than 0. 22 ng/ ml in all controls and IBS-D patients,while that was high in UC patients. Fecal MMP-9 levels were significantly correlated with the overall Mayo score( P 0. 001),the endoscopic score( P〈 0. 001), and the serum C-reactive protein levels( P = 0. 002) in UC patients. Additionally,fecal MMP-9 levels also showed significant correlation with fecal calprotectin in UC patients( r = 0. 492,P = 0. 013). Conclusion These results highlight fecal MMP-9 is a useful index in the differential diagnosis of UC,IBS-D and healthy controls,and it can be used to judge the disease activity of UC.
作者 杨婷 金妙玲
出处 《中国卫生检验杂志》 北大核心 2014年第8期1140-1142,共3页 Chinese Journal of Health Laboratory Technology
关键词 溃疡性结肠炎 MMP-9 疾病活动分数 钙卫蛋白 Ulcerative colitis MMP-9 Disease activity score Calprotectin
  • 相关文献

参考文献11

  • 1Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? [J]. Gut, 2006, 55 (3) : 426 -431.
  • 2Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies [J]. Inflamm Bowel Dis, 2008,14 (1) : 32 -39.
  • 3Kucharzik T, Maaser C, Lugering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies [J]. Inflamm Bowel Dis, 2006,12 (11) : 1068 - 1083.
  • 4Costa F, Mumolo MG, Bellini M, et al. Role of faecal ealprotectin as non - invasive marker of intestinal inflammation [ J ]. Dig Liver Dis, 2003, 35 (9) : 642 - 647.
  • 5Dabek M, Ferrier L, Roka R, et al. Luminal cathepsin g and prote- ase activated receptor 4 : a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis [ J ]. Am J Pathol, 2009, 175 (1) : 207 -214.
  • 6Manfredi MA, Zurakowski D, Rufo PA, et al. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pedi- atric patients with inflammatory bowel disease [ J ]. Inflamm Bowel Dis, 2008, 14 (8): 1091-1096.
  • 7Sutherland LR, Martin F. 5 - Aminosalicylic acid enemas in treat- ment of distal ulcerative colitis and proctitis in Canada[ J]. Dig Dis Sci,1987, 32(12 Suppl) : 64S- 66S.
  • 8Smith ER, Zurakowski D, Saad A, et al. Urinary biomarkers predict brain tumor presence and response to therapy[J].Clin Cancer Res, 2008, 14 (8) : 2378 -2386.
  • 9Lakatos G, Sipos F, Miheller P, et al, The behavior of matrix metal- loproteinase - 9 in lymphocytic colitis, collagenous colitis and ulcer- ative colitis[J]. Pathol Oncol Res, 2012, 18 (1) : 85 -91.
  • 10Kossakowska AE, Medlieott SAC, Edwards DR, et al. Elevated plasma gelatinase A ( MMP - 2) activity is associated with quies- cent Crohng Disease[J].Ann N Y Acad Sei, 1999, 878(1 ) : 578 -580.

同被引文献32

  • 1刘香,郑长青.炎症性肠病慢性腹泻的药物治疗[J].实用药物与临床,2005,8(6):7-9. 被引量:5
  • 2MOOIWEER E,SEVERS M,SCHIPPER ME,et al.Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients:a plea for deep remission[J].J Crohns Colitis,2015,9(1):50-55.
  • 3LAZEBNIK LBi GUSE N-ZADE MG,EFREMOV LI,et al.Fe- cal calprotectin as a biomarker effectiveness of various interven- tions in patients with inflammatory bowel disease[J].Eksp Klin Gastroenterol,2013,(8):11-16.
  • 4MORTENSEN JH,GODSKESEN LE,JENSEN MD,et al.Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type IQ Collagen Are Novel Serological Biomark- ers to Differentiate Crohn's Disease from Ulcerative Colitis[J].J Crohns Colitis,2015,9(10):863-872.
  • 5MARCHESI JR,HOLMES E,KHAN F,et al.Rapid and non- invasive metabonomic characterization of inflammatory bowel dis- ease[J].J Proteome Res,2007,6(2):546-551.
  • 6VERNIA P,GNAEDINGER A,HAUCK W,et al.Organic an- ions and the diarrhea of inflammatory bowel disease[J].Dig Dis Sci,1988,33(11):1353-1358.
  • 7PASTOR ROJO O,LPEZ SAN ROM NA,ALB NIZ ARBIZU E,et al.Serum lipopolysaccharide-binding protein in endotox- emic patients with inflammatory bowel disease[J].Inflamm Bowel Dis,2007,13(3):269-277.
  • 8LAKATOS PL,KISS LS,PALATKA K,et al.Serum lipopolysac- charide-binding protein and soluble CD14 are markers of disease activity in patients with CrohnrS disease[J].Inflamm Bowel Dis,2011,17(3):767-777.
  • 9KISIEL JB,YAB TC,NAZER HUSSAIN FT,et al.Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease[J].Aliment Pharmacol Ther,2013,37(5):546-554.
  • 10MORGAN XC,SEGATA N,HUITENHOWER C.Biodiversity and functional genomics in the human microbiome[J].Trends Genet,2013,29(1):51-58.

引证文献3

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部